Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04781088 | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 38 | Floor Backes, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05239143 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 180 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2026 |
| NCT05737199 | Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | active not recruiting | Phase 2 | 21 | Niigata University Medical & Dental HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05043922 | A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | active not recruiting | Phase 2 | 93 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT06483997 | Diet, Hepcidin, and Chemotherapy RDI | active not recruiting | — | 100 | George Washington UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04169997 | A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer(FLAMES) | active not recruiting | Phase 3 | 404 | Impact Therapeutics, Inc.INDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05786456 | e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study | active not recruiting | N/A | 23 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04204811 | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | active not recruiting | N/A | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT00565851 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 1,052 | National Cancer Institute (NCI)NIH | 3 | Dec 30, 2025 | clinicaltrials |
| NCT05220033 | Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer | active not recruiting | N/A | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04670068 | Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | active not recruiting | Phase 1 | 4 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J) | active not recruiting | Phase 2 | 16 | Verastem, Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.(SOLO-1) | active not recruiting | Phase 3 | 450 | AstraZenecaINDUSTRY | 15 | Dec 10, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT01230346 | Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer | active not recruiting | N/A | 493 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT01223248 | Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | active not recruiting | Phase 3 | 220 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Nov 4, 2025 | clinicaltrials |
| NCT02346747 | A Trial of Vigil for Participants With Ovarian Cancer(VITAL) | active not recruiting | Phase 2 | 92 | Gradalis, Inc.INDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06436248 | Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer(PROMISE) | active not recruiting | — | 24 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT02917798 | Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes | active not recruiting | — | 1,047 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT02828618 | Trial on Radical Upfront Surgery in Advanced Ovarian Cancer(TRUST) | active not recruiting | N/A | 797 | AGO Study GroupOTHER | 8 | Oct 3, 2025 | clinicaltrials |
| NCT03029403 | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 2 | 47 | University Health Network, TorontoOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06451263 | Nudge to Gynecologic Oncology | active not recruiting | N/A | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04511988 | Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal(BOVARY CE) | active not recruiting | N/A | 20 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05708703 | Assessing the Time Demands of Cancer | active not recruiting | — | 78 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT03776630 | Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors(GYNO-MIR) | active not recruiting | N/A | 363 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA) | active not recruiting | Phase 3 | 1,097 | pharmaand GmbHINDUSTRY | 24 | Jun 24, 2025 | clinicaltrials |
| NCT04024878 | NeoVax With Nivolumab in Patients With Ovarian Cancer | active not recruiting | Phase 1 | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT01953159 | Assessment of Paclitaxel-Induced Neuropathy | active not recruiting | — | 43 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009743 | O-RADS MRI System on Early Detection of Ovarian Cancer | active not recruiting | — | 2,549 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 50 | New Mexico Cancer Research AllianceOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04575961 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer(PERCEPTION) | active not recruiting | Phase 2 | 33 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT05156892 | Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer(TICTOC) | active not recruiting | Phase 1 | 44 | Anthony Joshua, FRACPOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06884345 | METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05953883 | Proteogenomic Signatures Analysis In Ovarian Cancer(PROGENITOR) | active not recruiting | N/A | 24 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT05591131 | Genetic Testing in African Americans(GTM-I) | active not recruiting | N/A | 21 | Augusta UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT05857397 | A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America(CONOR) | active not recruiting | — | 64 | Latin American Cooperative Oncology GroupOTHER | 2 | Feb 12, 2025 | clinicaltrials |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | active not recruiting | Phase 3 | 489 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 2 | Feb 10, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 11, 2026source: clinicaltrials